William Starbird, MD
Family Medicine · North Branch, MINPI 1629172069
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Dexcom, Inc. accounts for 78.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $6,631 and has fallen 94.9% since, to $339 in 2025. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $71.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$6K
- Novo Nordisk$521
- Lilly USA, LLC$222
- AstraZeneca$149
- AbbVie$138
- Abbott$120
- plus $602 from 13 others
What the payments were for
- Speaking & faculty fees$4,33654%
- Travel & lodging$1,74522%
- Food & beverage$1,95024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 7 | $6,278 |
| Novo Nordisk | 40 | $521 |
| Lilly USA, LLC | 14 | $222 |
| AstraZeneca | 9 | $149 |
| AbbVie(2 entities) | 7 | $138 |
| Abbott | 6 | $120 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Amgen | 4 | $84 |
| Exact Sciences | 5 | $84 |
| Alkermes, Inc. | 3 | $80 |
| Boehringer Ingelheim | 4 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Pfizer | 2 | $44 |
| Mayne Pharma Commercial LLC | 1 | $27 |
| RGH Enterprises LLC | 1 | $27 |
| GSK | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$6,248
How this compares
$8,030 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $53,358 |
| EliquisApixaban | 39 | $48,568 |
| OzempicSemaglutide | 21 | $34,947 |
| TrulicityDulaglutide | 14 | $31,842 |
| JanuviaSitagliptin Phosphate | 15 | $24,081 |
| FarxigaDapagliflozin Propanediol | 14 | $22,806 |
| XareltoRivaroxaban | 19 | $21,597 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $11,372 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $10,784 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $9,715 |
| Novolog FlexpenInsulin Aspart | 26 | $7,634 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $7,496 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,946 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $6,024 |
| Atorvastatin Calcium | 222 | $3,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $59 | $60,85560 claims |
| PfizerEliquis | $44 | $48,56839 claims |
| Novo NordiskOzempic | $521 | $34,94721 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $149 | $34,17829 claims |
| Lilly USA, LLCTrulicity | $222 | $31,84214 claims |
| MerckJanuvia | $12 | $24,08115 claims |
| GSKTrelegy Ellipta | $24 | $6,94611 claims |
| AbbVieSynthroid | $138 | $88715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in North Branch
- Antonio DicarloNorth Branch$40K
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.